Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is on track for success due to their innovative approach to treating neurodegenerative diseases, strong financial position with a valuation of $520M and a potential $540M in peak annual sales for ZUNVEYL, and the company's ability to build a strong commercial team and secure licensing partnerships. Risks include potential competition, slow market uptake, and setbacks in clinical testing. The recent settlement agreement eliminates future royalty and milestone payments, providing a more streamlined financial position. With additional contracting expected in the near-term and modest revisions to our forecasts, we maintain a Buy rating and a 12-month price target of $18.

Bears say

Alpha Cognition is expected to face challenges in its commercial development program for ZUNVEYL due to potential pricing pressures, payor push-back, and competition from generic and other branded products. The company's current financial results show a net loss in the first quarter of 2026, and while its revenue projections are positive, there is still a risk of slower-than-expected market uptake. Furthermore, the potential dilution risk for long-term shareholders is a concern, and the success of the ongoing clinical trials and the timely launch of ZUNVEYL are key factors for the company's future performance.

ACOG has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACOG has a Strong Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.